The aim in the current treatment of Parkinson's disease is to delay L-Dopa
administration and to keep the L-Dopa dosage as low as possible. Such a tre
atment strategy can delay the onset of late motor complications and reduce
their severity. L-Dopa remains the most potent anti-parkinsonian medication
, but its use for the initial therapy of Parkinson's disease is limited to
elderly patients. In all other cases, dopamine agonists, budipine, amantadi
ne and selegiline are primarily used. With the occurrence of late motor com
plications continuous dopamine receptor stimulation becomes essential. In t
his situation, combination therapy has to be individualized. with dopamine
agonists playing a key role. In addition, COMT inhibitors, budipine, amanta
dine and selegiline may be used. Anticholinergic drugs are of very limited
importance in the current treatment of Parkinson's disease.